REMARKS

In the parent case, the Examiner entered a restriction requirement with respect to claim 8 in the office action of March 20, 2001. Applicant elected all of the claims of the first group (excluding claim 8). This divisional preserves claim 8 and rewrites it in independent form as claim 15. All of the other limitations remain the same in claim 15 as were expressed in allowed claim 1 of the parent case. It is submitted that this divisional is in form for allowance.

Attached hereto is a marked-up version of the changes made to the specification and claims by the current amendment. The attached page is captioned "**Version with markings to show changes made.**"

Reconsideration and allowance is respectfully requested.

Respectfully submitted,

Edmund J. Sease, Reg. No. 24,741
ZARLEY, McKEE, THOMTE, VOORHEES
& SEASE
801 Grand Avenue, Suite 3200
Des Moines, Iowa 50309-2721
Phone No. (515) 288-3667
Fax No. (515) 288-1338
CUSTOMER NO: 22885

Attorneys of Record

- rl -

PRELIMINARY AMENDMENT — VERSION WITH MARKINGS TO SHOW CHANGES MADE

In the Claims

Claim 2 (Amended)

The method of claim [1] 15 wherein the glucagon-like peptide-1 is selected from (a) a peptide which comprises the amino acid sequence of glucagon-like peptide-1, and (b) a variant peptide comprising an amino acid sequence that differs from the sequence of glucagon-like peptide-1 by one or more [substittions] substitutions, deletions or insertions wherein said variant binds to the glucagon-like peptide-1 amide receptor protein and has a corresponding biological affect on insulin secretion as GLP-1 (7-36) amide.

Claim 7 (Amended)

The method of claim [1] 15, further comprising using an agent which enhances the half-life *in vivo* of the compound.

Claim 9 (Amended)

The method of claim [1] 15 wherein the patient is simultaneously infused with a combined glucose/GLP-1 or its biologically active analogue.

Claim 10 (Amended)

The method of claim [1] 15 wherein the patient is first infused with glucose and then later with GLP-1.

Claim 11 (Amended)

The method of claim [1] 15 wherein the dose of GLP-1 is a bolus dose intravenously administered at from .05 nmol to 100 nmol.

Claim 12 (Amended)

The method of claim [1] 15 wherein the dose is a bolus subcutaneous method at from 10 nmol to 1000 nmol.

Claim 13 (Amended)

The method of claim [1] 15 wherein the patient is infused with a dose of GLP-1 or a biologically active analogue continuously infused by I.V. at from 0.1 pmol/kg/min to 10 pm/kg/min.

Claim 14 (Amended)

The method of claim [1] 15 wherein dosing is continuous subcutaneous infusion at a dose of from 0.5 to 50 pm/kg/min.

Claim 15 (New)

A method of detecting impaired glucose tolerance of individuals by evaluation of β-cells secretory capacity, comprising:

infusing the individual with glucose and a glucagon-like peptide-1 or its biologically active analogue expressed by a polynucleotide wherein said analogue binds to the glucagon-like peptide amide receptor protein and has a corresponding effect on insulin secretion as GLP-1 (7-36) amide; and thereafter

measuring the insulin and C-peptide responses against standard responses of healthy subjects to determine if the individual has impaired β-cell function.